Aromatase inhibitors in early breast cancer therapy: a variety of treatment strategies.

about

Aromatase and dual aromatase-steroid sulfatase inhibitors from the letrozole and vorozole templates.

P2860

Q35207866-FB9E9B04-A282-4BF6-98C3-E287A1B14470

P2860

Aromatase inhibitors in early breast cancer therapy: a variety of treatment strategies.

Item

http://www.wikidata.org/entity/Q36675384

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Aromatase inhibitors in early breast cancer therapy: a variety of treatment strategies.

@ast

Aromatase inhibitors in early breast cancer therapy: a variety of treatment strategies.

@en

type

Item

label

Aromatase inhibitors in early breast cancer therapy: a variety of treatment strategies.

@ast

Aromatase inhibitors in early breast cancer therapy: a variety of treatment strategies.

@en

prefLabel

Aromatase inhibitors in early breast cancer therapy: a variety of treatment strategies.

@ast

Aromatase inhibitors in early breast cancer therapy: a variety of treatment strategies.

@en

P1476

Aromatase inhibitors in early breast cancer therapy: a variety of treatment strategies.

@en

P2093

J Michael Dixon

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Use of aromatase inhibitors in breast carcinoma.

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group.

Lessons from the use of aromatase inhibitors in the neoadjuvant setting.

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.

Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*.

A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men.

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

Neoadjuvant endocrine therapy of breast cancer: a surgical perspective.

P304

2465-2479

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.7.18.2465

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2006-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17150002

http://www.w3.org/2001/XMLSchema#string

Aromatase inhibitors in early breast cancer therapy: a variety of treatment strategies.

about

P2860

P2860

Aromatase inhibitors in early breast cancer therapy: a variety of treatment strategies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698